Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma PDF Print E-mail
Wednesday, 09 February 2011 16:24
According to the results of this placebo-controlled study, methotrexate is an effective treatment for juvenile localised scleroderma (JLS).

The authors note that JLS is a chronic progressive fibrotic process of the skin causing permanent disability and aesthetic damage.  There is deep tissue involvement, and around 20% will have another organ involved.  Although it is the most common form of scleroderma in children, it remains poorly understood.  There is no universally accepted treatment for this condition; however methotrexate (MTX) has been reported to be beneficial.   

In this study, they randomised 70 patients aged 6-17 years with active JLS to receive double-blind treatment with methotrexate (15mg/m2; max 20mg; n=46) or placebo (n=24) once weekly, alongside oral prednisolone (1mg/kg/day; max 50mg) for the initial three months (followed by one month of dose tapering).  Treatment was continued for 12 months, or until treatment failure, if sooner.  Patients were assessed during six clinical visits throughout the treatment period.  The primary endpoint was the rate of response to treatment at the end of the 12 month period.  Response was defined as no new lesions, a skin score rate (SSR) score of a target lesion <1, and a decrease in lesion temperature by at least 10% compared to baseline.

Around half of the enrolled patients completed the 12-month study, including 67.4% of the MTX group and 29.2% of the placebo group (premature discontinuation due to disease flare in all cases).  All 70 enrolled patients were included in the intention-to-treat analysis of efficacy.  The main findings were as follows:

• At the final visit, 67.4% of the MTX group and 29.2% of the placebo-treated patients had responded to treatment (p=0.001).
• After an initial response, disease relapsed in 15 MTX patients (32.6%) and 17 placebo (70.8%) (p<0.005).
• The likelihood to experience a flare of disease in the MTX group was around one third of that in the placebo group (hazard ratio [HR] 2.82, 95% CI 1.40 - 5.66).
• New lesions appeared in three MTX patients (6.5%) vs. four of those on placebo (16.7%), mean SSR decreased from 1 to 0.79 with MTX vs. 1.1 on placebo (p=0.011), and the mean target lesion temperature decreased by 44.4% vs. 12.1%, respectively (p=0.024)

The authors conclude that methotrexate in combination with a short course of prednisone is beneficial and well tolerated as a treatment for localised scleroderma in children.

Source: Pocock, N. (2011), "Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma"; taken from original article here.
 
More articles :

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» The Importance Of Exercise

Exercise is important for everyone. There are many forms of exercise including aerobics, cycling, walking the dog, and even stair climbing and home chores. These are all good but if you have it may be necessary for you to also have a therapeutic...

» Unite Against Scleroderma 2012

For our second year running, the Scleroderma Care Foundation will be hosting its “Unite Against Scleroderma” Awareness Walk around the , Port of Spain. Scheduled to start from 3:00pm, the Walk would be held on Sunday May 6th 2012 and cover one...

» Long-Term Outcomes of Scleroderma Renal Crisis

In a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by...

» Methotrexate Effective In Juvenile Localized Scleroderma

is effective in when given with a short course of steroids, an Italian randomized study confirmed.Among children ages 6 to 17 receiving methotrexate, 67.4% completed the yearlong trial without flaring, compared with 29.2% of those given placebo...

» Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis

Marco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, Maureen D Mayes, Vivien M Hsu, Patrick Carpentier, Fredrick M Wigley, Carol M Black, Barri J Fessler, Peter A Merkel, Janet E Pope, Nadera J Sweiss, Mittie K Doyle, Bernhard Hellmich,...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh